Intralesional Injection of Vitamin D3 for Treatment of Cutaneous Warts: A Randomized, Double-Blind, Placebo-Controlled Trial
Journal of Primary Care & Community Health · 2025
DOI: 10.1177/21501319251365853 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Primary Care & Community Health, 2025. Verfasst von Stephen P Merry und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Family Medicine, Mayo Clinic, Rochester, MN, USA. Hauptthemen laut MEDLINE: Warts, Cholecalciferol, Vitamins. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: professorship endowment from Parker D. Sanders & Isabella G. Sanders for Dr. Tom D. Thacher, Professor of Family Medicine, Mayo Clinic, Rochester..
Abstract (Originalsprache)
Introduction
Treatment of cutaneous warts with intralesional vitamin D3 has demonstrated promising results in over 35 studies with methodological limitations.
Methods
We conducted a randomized, double-blind, placebo-controlled trial in our primary care procedure clinic of intralesional vitamin D3 12 000 IU vs placebo in cutaneous warts every 4 weeks up to 3 times. Warts were assessed 4, 8, 12, and 24 weeks after the initial injection. The primary outcome was complete wart resolution. Reduction in wart size was a secondary outcome.
Results
Between October 2020 and April 2023, we enrolled 77 participants with 1 or more cutaneous warts (41 and 36 in vitamin D3 and placebo groups, respectively) with untreated (32%) and recalcitrant (69%) warts. At 24 weeks, the index wart had resolved in 12 (30%) of vitamin D3 and 10 (31%) placebo participants. Treatment with vitamin D3 had no effect on wart surface area in an adjusted model nor wart resolution in analysis adjusted for baseline wart size, multiple warts, and the vehicle (OR 0.31 [95% CI] 0.01-10.3; P = 0.51).
Conclusions
These results demonstrate a lack of benefit of intralesional vitamin D3 in cutaneous warts. ( ClinicalTrials.gov number NCT04278573)
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Family Medicine, Mayo Clinic, Rochester, MN, USA.
- Division of General Internal Medicine, Mayo Clinic, Rochester, MN, USA.
- Department of Pharmacy (Stanek), Mayo Clinic, Rochester, MN, USA.
ORCID-Profile: Stephen P Merry, David N Brennan, Michelle J Duvall, Joseph B Stanek, Erin K O'Dowd, Tom D Thacher
Förderung
- professorship endowment from Parker D. Sanders & Isabella G. Sanders for Dr. Tom D. Thacher, Professor of Family Medicine, Mayo Clinic, Rochester.
Zitieren
APA
Merry, S. P., Brennan, D. N., Duvall, M. J., Stanek, J. B., O'Dowd, E. K., & Thacher, T. D. (2025). Intralesional Injection of Vitamin D3 for Treatment of Cutaneous Warts: A Randomized, Double-Blind, Placebo-Controlled Trial. Journal of Primary Care & Community Health. https://doi.org/10.1177/21501319251365853
Vancouver
Merry SP, Brennan DN, Duvall MJ, Stanek JB, O'Dowd EK, Thacher TD. Intralesional Injection of Vitamin D3 for Treatment of Cutaneous Warts: A Randomized, Double-Blind, Placebo-Controlled Trial. Journal of Primary Care & Community Health. 2025. doi:10.1177/21501319251365853
BibTeX
@article{Merry2025,
author = {Merry, Stephen P and Brennan, David N and Duvall, Michelle J and Stanek, Joseph B and O'Dowd, Erin K and Thacher, Tom D},
title = {Intralesional Injection of Vitamin D3 for Treatment of Cutaneous Warts: A Randomized, Double-Blind, Placebo-Controlled Trial},
journal = {Journal of Primary Care & Community Health},
year = {2025},
doi = {10.1177/21501319251365853}
}
EUVIMED